This Moving Average Strategy Beats Buy and Hold by Nearly 3-to-1
Moving averages (MAs) are one of the most popular trading tools. Their popularity may be due to their simplicity. Before there were calculators or computers, a 10-day simple moving average could be found by adding up the last 10 closing prices and mo...Read More>>>

Catalyst Pharmaceuticals Inc (CPRX) Q1 2019 Earnings Call Transcript
Image source: The Motley Fool. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)Q1 2019 Earnings CallMay. 13, 2019, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings. Welcome to Catalyst ...Read More>>>

CytomX Therapeutics, Inc. (CTMX) Q1 2019 Earnings Call Transcript
Image source: The Motley Fool. CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2019 Earnings Call May 9, 2019, 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen and...Read More>>>

ChromaDex Corporation (CDXC) Q1 2019 Earnings Call Transcript
Image source: The Motley Fool. ChromaDex Corporation (NASDAQ:CDXC) Q1 2019 Earnings Call May 9, 2019, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Ladies and gentlemen, thank you for st...Read More>>>

Week In Review: Human Gene Editing Scandal Revisited; Can China Biopharma Continue To Expand? News O
Industry Insights In a deeply researched Wall Street Journal article, Preetika Rana provides extraordinary depth into the story of Dr. Jiankui He, the man who announced last November he had used Crispr-Cas9 gene editing to alter human embryos in eigh...Read More>>>


To analyze our business performance, determine financial forecasts and help
develop long-term strategic plans, we review the following key business metric:

As of As of
December 31, June 30,
(in thousands) 2016 2017 2017 2018
Paying users 575 606 598 616

Paying users

We define a paying user as an individual customer of our survey platform or
form-based application, a seat within a SurveyMonkey Enterprise deployment or a
subscription to one of our purpose-built solutions. One person would count as
multiple paying users if the person had more than one paid license at the end of
the period. For example, if an individual paying user also had a designated seat
in a SurveyMonkey Enterprise deployment, we would count that person as two
paying users.  

Lipocine Inc. (LPCN)

Marathon Bar Corp. (“Marathon Bar”) was incorporated on October 13, 2011, in the
State of Delaware. On July 24, 2013, Marathon Bar and MBAR Acquisition Corp.
(“Merger Sub”), a wholly owned subsidiary of Marathon Bar, and Lipocine
Operating Inc. (“Lipocine Operating”), a privately held company incorporated in
Delaware, executed an Agreement and Plan of Merger (“Merger Agreement”).
Pursuant to the Merger Agreement, Merger Sub merged with and into Lipocine
Operating and Lipocine Operating was the surviving entity. Additionally,
pursuant to the Merger Agreement, Marathon Bar changed its name to Lipocine Inc.
The Merger is accounted for as a reverse-merger and recapitalization.


We are a specialty pharmaceutical company focused on applying our oral drug
delivery technology for the development of pharmaceutical products in the area
of men’s and women’s health.  

Liberty Property Trust (LPT)

Liberty Property Trust (the “Trust”) is a self-administered and self-managed
Maryland real estate investment trust (a “REIT”). Substantially all of the
Trust’s assets are owned directly or indirectly, and substantially all of the
Trust’s operations are conducted directly or indirectly, by its subsidiary,
Liberty Property Limited Partnership, a Pennsylvania limited partnership (the
“Operating Partnership” and, together with the Trust and their consolidated
subsidiaries, the “Company”).
The Company completed its initial public offering in 1994 to continue and expand
the commercial real estate business of Rouse & Associates, a Pennsylvania
general partnership, and certain affiliated entities (collectively, the
“Predecessor”), which was founded in 1972. As of December 31, 2017, the Company
owned and operated 461 industrial and 48 office properties (the “Wholly Owned
Properties in Operation”) totaling 87.3 million square feet.  

Eidos Therapeutics, Inc. (EIDX)

We are a clinical stage biopharmaceutical company focused on addressing the
large and growing unmet need in diseases caused by transthyretin, or TTR,
amyloidosis, or ATTR. We seek to treat this well-defined family of diseases by
targeting them at their collective source by stabilizing TTR. TTR is a protein
that occurs naturally in the form of a tetramer (a molecular structure
consisting of four identical subunits, or monomers) and performs multiple
beneficial roles, including the transport of essential hormones and vitamins.
Over 25 years of research have shown that ATTR is uniformly driven by
destabilization of the TTR tetramer, stemming from either specific gene
mutations or aging. TTR destabilization drives an irreversible dissociation of
the tetramer into monomers, which subsequently aggregate and deposit
predominantly in the heart and peripheral nervous system, leading to organ
damage, loss of organ function, and eventual death if left untreated.  

Sonos, Inc. (SONO)

Sonos was founded with a clear mission–to fill every home with music. This
mission led us to invent wireless multi-room home audio. Sonos transforms the
way people live and interact by restoring the shared experience of music
throughout the home. Our home sound system provides an immersive listening
experience created by our thoughtfully designed speakers and components, our
proprietary software platform and the ability to wirelessly stream the content
our customers love from the services they prefer.

Sonos sits at the intersection of emerging trends driving the future of home
entertainment. The proliferation of streaming services and the rapid adoption of
voice assistants are significantly changing audio consumption habits and how
consumers interact with the internet. As the leading home sound system for
consumers, content partners and developers, Sonos is poised to capitalize on the
large market opportunity created by these dynamics.